Confidence Analytics

Participants offered feedback to DOH staff questions related to their medical cannabis testing requirements and then posed questions of their own to officials.

Officials outlined a transition period to take on accreditation authority in parallel with revising standards, including method approval and when enforcement of new standards would start.

Legislation to alter a planned transfer of cannabis lab accreditation authority was broadly praised by the sponsor, agency leaders, and cannabis sector stakeholders. 

By the end of Tuesday, Representatives tasked with oversight of the adult-use cannabis market were scheduled to have heard five bills and considered moving two in the first days of the week.

Lab representatives and other stakeholders pointed out discrepancies, redundancies, and costs related to proposed lab quality standards leading staff to ultimately choose to rework the rules.

Staff laid out changes in the latest lab accreditation rulemaking draft, including a lower cost of implementation and a waiver process around in-matrix proficiency testing.

A mostly new team at the DOH Medical Cannabis Program solicited feedback on potential revisions to rules on compliant products, testing, labeling, and logos.

After a background on the draft rulemaking and method list for cannabis laboratory standards, stakeholders raised a lot of concerns and questions around expense and implementation.

Pausing emergency rulemaking which would lower action levels for some pesticides didn’t preclude public comments critical of the approach taken by agency staff to the overall situation.

A bill adding restrictions on manufacturing and sales of hemp cannabinoid products was generally well received, but many speakers disagreed with the allowable THC limits.